A First – Smartphone Diagnostic Device Replicates Quality of Lab Blood Test
|
By LabMedica International staff writers Posted on 09 Feb 2015 |

Image: Newly developed diagnostic smartphone accessory device successfully performed point-of-care HIV and syphilis tests in Rwanda from finger-prick whole blood in 15 minutes, operated by healthcare workers easily trained via a software app (Photo courtesy of Samiksha Nayak for Columbia Engineering).
Researchers have developed a hand-held smartphone accessory that can perform a low-cost, point-of-care (POC), lab-quality test that simultaneously detects 3 infectious disease markers from a single finger-prick blood sample in only 15 minutes. The device can also be further developed to test for additional biomarkers.
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
In a multi-institutional collaboration, the team of researchers, led by Samuel K. Sia, associate professor of biomedical engineering at Columbia Engineering (New York, NY, USA), developed and field-tested the miniature device that, for the first time, replicates all mechanical, optical, and electronic functions of a lab-based blood test. Specifically, it performs an enzyme-linked immunosorbent assay (ELISA), without requiring stored energy as all necessary power is drawn from the smartphone. It also performs a triplexed immunoassay not currently available in a single test format: HIV antibody, treponemal-specific antibody for syphilis, and non-treponemal antibody for active syphilis infection.
Prof. Sia’s innovative accessory (or dongle) was recently piloted by healthcare workers in Rwanda, who trained via a software app then tested 96 patients from prevention-of-mother-to-child-transmission clinics or voluntary counseling and testing centers.
“Our work shows that a full laboratory-quality immunoassay can be run on a smartphone accessory,” said Prof. Sia, “Coupling microfluidics with recent advances in consumer electronics can make certain lab-based diagnostics accessible to almost any population with access to smartphones. This kind of capability can transform how health care services are delivered around the world.”
Prof. Sia’s team built upon their previous work in miniaturizing diagnostics hardware for rapid POC diagnosis of HIV, syphilis, and other sexually transmitted diseases. “We know that early diagnosis and treatment in pregnant mothers can greatly reduce adverse consequences to both mothers and their babies,” Sia notes. The team developed the dongle to be small and light enough to fit into one hand, and to run assays on disposable plastic cassettes with pre-loaded reagents, where disease-specific zones provide an objective read-out, much like an ELISA assay.
Prof. Sia estimates the dongle will have a manufacturing cost of USD 34, much lower than the USD 18,450 that typical ELISA equipment runs.
The team made two main innovations to achieve low power consumption, a must in places without dependable electricity. They eliminated the power-consuming electrical pump by using a “one-push vacuum,” where a user mechanically activates a negative-pressure chamber to move a sequence of reagents pre-stored on a cassette. The process is durable, requires little user training, and needs no maintenance or additional manufacturing. The team was able to implement a second innovation to remove the need for a battery by using the audio jack for transmitting power as well as for data transmission. And, because audio jacks are standardized among smartphones, the dongle can be attached to any compatible device (including iPhones and Android phones) in a simple plug-and-play manner.
During the field testing in Rwanda, healthcare workers were given 30 minutes of training, which included a user-friendly interface, step-by-step pictorial directions, built-in timers to alert to next steps, and records of test results for later review.
The work, by Laksanasopin T, Guo TW, et al., was published February 4, 2015, in the journal Science Translational Medicine.
Related Links:
Columbia Engineering
Latest Immunology News
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreMolecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








